{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:33:05Z","timestamp":1790184785348,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:19:31Z","timestamp":1711185571000},"page":"365-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Psoriasis Treatment Pipeline"],"prefix":"10.1016","volume":"42","author":[{"given":"Jason E.","family":"Hawkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Al-Saedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salsabeal","family":"Al-Saedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delaney T.","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eingun James","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.det.2024.02.006_bib1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.det.2024.02.006_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/jdv.15339","article-title":"Severity, heterogeneity and systemic inflammation in psoriasis","volume":"33","author":"Christophers","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.006_bib5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.det.2024.02.006_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaci.2014.05.046","article-title":"Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis","volume":"135","author":"Harden","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.det.2024.02.006_bib8","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.det.2024.02.006_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/exd.12350","article-title":"Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases","volume":"23","author":"Kim","year":"2014","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.006_bib13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib14","first-page":"917","article-title":"Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis","volume":"123","author":"van den Bogaard","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.det.2024.02.006_bib15","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-022-01748-6","article-title":"Tapinarof Cream 1%: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.det.2024.02.006_bib16","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial","volume":"87","author":"Strober","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib18","doi-asserted-by":"crossref","DOI":"10.25251\/skin.7.supp.194","article-title":"Tapinarof Inhibits the Formation, Cytokine Production, and Persistence of Resident Memory T Cells In\u00a0Vitro","volume":"7","author":"Mooney","year":"2023","journal-title":"SKIN The Journal of Cutaneous Medicine"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1210\/er.2013-1053","article-title":"Clinical and molecular genetics of the phosphodiesterases (PDEs)","volume":"35","author":"Azevedo","year":"2014","journal-title":"Endocr Rev"},{"issue":"5403","key":"10.1016\/j.det.2024.02.006_bib20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.283.5403.848","article-title":"CD3- and CD28-dependent induction of PDE7 required for T cell activation","volume":"283","author":"Li","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.det.2024.02.006_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.116.232819","article-title":"Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes","volume":"358","author":"Dong","year":"2016","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"11","key":"10.1016\/j.det.2024.02.006_bib22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/bjd\/ljad182","article-title":"Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study","volume":"189","author":"Kircik","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.det.2024.02.006_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.det.2024.02.006_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"15","key":"10.1016\/j.det.2024.02.006_bib28","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279","volume":"66","author":"Leit","year":"2023","journal-title":"J\u00a0Med Chem"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40744-021-00305-z","article-title":"Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study","volume":"8","author":"Mease","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jdv.18818","article-title":"Pharmacology of orismilast, a potent and selective PDE4 inhibitor","volume":"37","author":"Silverberg","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.02.006_bib31","series-title":"Efficacy and safety of orismilast in patients with moderate-to-severe psoriasis: results from the phase IIb IASOS trial","author":"Warren","year":"2023"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/jdv.18812","article-title":"Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets","volume":"37","author":"Warren","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.02.006_bib33","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.lanepe.2023.100639","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenlove","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.det.2024.02.006_bib34","article-title":"A\u00a0Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of\u00a0Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER 1","author":"Bissonnette","year":"2023","journal-title":"World Congress of Dermatology (WCD)"},{"key":"10.1016\/j.det.2024.02.006_bib35","series-title":"DC-806, an oral IL-17A inhibitor: proof-of-concept in adults with mild-to-moderate psoriasis. American Academy of Dermatology Annual Meeting. March 17-21","first-page":"S042","author":"Lu","year":"2023"},{"key":"10.1016\/j.det.2024.02.006_bib36","doi-asserted-by":"crossref","first-page":"1186455","DOI":"10.3389\/fimmu.2023.1186455","article-title":"Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies","volume":"14","author":"Brembilla","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2024.02.006_bib37","first-page":"127","article-title":"Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Psoriasis (Auckl)"},{"issue":"3","key":"10.1016\/j.det.2024.02.006_bib38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/bjd\/ljac089","article-title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III\/IIIb trials","volume":"188","author":"Kokolakis","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.02.006_bib39","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/IJN.S297631","article-title":"Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy","volume":"16","author":"Sun","year":"2021","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"10.1016\/j.det.2024.02.006_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jaad.2019.03.056","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A\/F nanobody, in moderate-to-severe psoriasis","volume":"81","author":"Svecova","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10284","key":"10.1016\/j.det.2024.02.006_bib41","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.det.2024.02.006_bib42","doi-asserted-by":"crossref","first-page":"2209920","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis","volume":"15","author":"Klint","year":"2023","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.det.2024.02.006_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/bjd\/ljad186","article-title":"Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment","volume":"189","author":"Gerdes","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13555-021-00677-8","article-title":"Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond","volume":"12","author":"Sugiura","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.det.2024.02.006_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdermsci.2018.01.012","article-title":"Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin","volume":"90","author":"Akiyama","year":"2018","journal-title":"J\u00a0Dermatol Sci"},{"issue":"10281","key":"10.1016\/j.det.2024.02.006_bib46","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.det.2024.02.006_bib47","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: First Approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"issue":"26","key":"10.1016\/j.det.2024.02.006_bib48","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of Spesolimab for Generalized Pustular Psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2024.02.006_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13555-022-00835-6","article-title":"Design of Effisayil 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis","volume":"13","author":"Morita","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.det.2024.02.006_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an\u00a0international, multicentre, randomised, placebo-controlled trial","author":"Morita","year":"2023","journal-title":"Lancet"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:38:51Z","timestamp":1716500331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000184"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.006","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Psoriasis Treatment Pipeline","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}